S 1954
Biosimilar Red Tape Elimination Act
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 8:44 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
The Biosimilar Red Tape Elimination Act aims to streamline the process for determining if a biosimilar biological product is interchangeable with its original reference product. It modifies key regulations within the Public Health Service Act to reduce barriers to licensure, particularly by clarifying the criteria for interchangeability and shortening the time it takes for a biosimilar product to be deemed interchangeable. The bill also addresses exclusivity periods for biosimilars to ensure a balance between incentivizing innovation and providing market stability.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.